InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Mann Brenda, VP of Research & Development. Officer active across 1 company, notably Eyegate Pharmaceuticals INC. Aggregated, 7 filings have been published. Activity tracked since 4 May 2021. The latest transaction was filed on 2 November 2021 (Retenue fiscale). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Mann Brenda
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
62 shares@ US$1.983.0% of flowCommon StockSEC:0001104659-21-133652:0
62 shares@ US$2.015.1% of flowCommon StockSEC:0001104659-21-123266:0
61 shares@ US$1.814.4% of flowCommon StockSEC:0001104659-21-112937:0
63 shares@ US$2.406.0% of flowCommon StockSEC:0001104659-21-100197:0
154 shares@ US$3.7022.8% of flowCommon StockSEC:0001104659-21-089443:0
155 shares@ US$4.1925.4% of flowCommon StockSEC:0001104659-21-077763:0
191 shares@ US$4.1331.2% of flowCommon StockSEC:0001104659-21-061946:0
7 of 7 declarations
About Mann Brenda
Brenda Mann is the Vice President of Research & Development at Eyegate Pharmaceuticals Inc. She is responsible for leading research and development initiatives aimed at innovating and improving the company's products.
